Therefore, a more targeted analysis of the peripheral effects of CSF1R inhibition in ongoing or planned clinical trials is necessary, to better ponder the long-term side effects of potential therapies for Alzheimer’s disease. This evidence concerns the gene CSF1R and Alzheimer disease.